{"id":747644,"date":"2023-04-13T17:45:20","date_gmt":"2023-04-13T21:45:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-canaccord-genuity-2023-horizons-in-oncology-virtual-conference\/"},"modified":"2023-04-13T17:45:20","modified_gmt":"2023-04-13T21:45:20","slug":"olema-oncology-to-participate-in-canaccord-genuity-2023-horizons-in-oncology-virtual-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-canaccord-genuity-2023-horizons-in-oncology-virtual-conference\/","title":{"rendered":"Olema Oncology to Participate in Canaccord Genuity 2023 Horizons in Oncology Virtual Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN FRANCISCO, April  13, 2023  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cjBRqffYwKuZJCxzb7gJe7PIlxw6VabvCWhOmlkJ6IGEHVTWUI6pfmIt01MkRaIXAWEXCv5LTY4nMZZfU1Ga2x6vfFe2vDqPJnKbxH1IMwU=\" rel=\"nofollow noopener\" target=\"_blank\">Olema Pharmaceuticals, Inc.<\/a> (\u201cOlema\u201d, \u201cOlema Oncology\u201d, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women\u2019s cancers, today announced that Sean Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a panel on \u201cER+\/HER2- Breast Cancer\u201d at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference on Thursday, April 20, 2023, at 2:00 p.m. ET.<\/p>\n<p>\n        <strong>About Olema Oncology<\/strong><br \/>\n        <br \/>Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women\u2019s cancers. Olema\u2019s lead product candidate, OP-1250, is a proprietary, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated both as a single agent in an ongoing Phase 2 clinical trial, and in combination with CDK4\/6 inhibitors (palbociclib and ribociclib) and a PI3Ka inhibitor (alpelisib), in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. OP-1250 has been granted FDA Fast Track designation for the treatment of ER+\/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4\/6 inhibitor. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts.<\/p>\n<p align=\"left\">\n        <u>IR Contact<\/u>:<br \/>Shane Kovacs, Chief Operating and Financial Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8bRDVaHP2-Pxw-AAFdRh-2uJ8xxsGtNGl5_Nb9_Q5au7acIQCw4t9tBB6K41w7CuTqt5U5lCD4aczIbElm9lbw==\" rel=\"nofollow noopener\" target=\"_blank\">ir@olema.com<\/a><\/p>\n<p>\n        <u>Media Contact<\/u>:<br \/>Ignacio Guerrero-Ros, Ph.D., Russo Partners<br \/>646-942-5604<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lyamtTooyResQRAf8wClXWa4wfrsN_BYS9GLBQ52zQoIq3AZ_zoNiZVuBDkh9pDO-iy8yHlNPJb5gJTefyjm8BoqgC5ierubsPA-CudqpZVYEyk8WL4cETyppflk7_2VBgXUzW0G3bEHbRodZiV-IQ==\" rel=\"nofollow noopener\" target=\"_blank\">ignacio.guerrero-ros@russopartnersllc.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNzczMSM1NTI1OTUzIzIyMDM1MTU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDg5NzAwZjEtM2M0MS00YTY4LWI5MzQtNTBhNjExNDI3MDQyLTEyMTUwNjg=\/tiny\/Olema-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN FRANCISCO, April 13, 2023 (GLOBE NEWSWIRE) &#8212; Olema Pharmaceuticals, Inc. (\u201cOlema\u201d, \u201cOlema Oncology\u201d, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women\u2019s cancers, today announced that Sean Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a panel on \u201cER+\/HER2- Breast Cancer\u201d at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference on Thursday, April 20, 2023, at 2:00 p.m. ET. About Olema Oncology Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women\u2019s cancers. Olema\u2019s lead product candidate, OP-1250, is a proprietary, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-canaccord-genuity-2023-horizons-in-oncology-virtual-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Olema Oncology to Participate in Canaccord Genuity 2023 Horizons in Oncology Virtual Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-747644","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Olema Oncology to Participate in Canaccord Genuity 2023 Horizons in Oncology Virtual Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-canaccord-genuity-2023-horizons-in-oncology-virtual-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Olema Oncology to Participate in Canaccord Genuity 2023 Horizons in Oncology Virtual Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN FRANCISCO, April 13, 2023 (GLOBE NEWSWIRE) &#8212; Olema Pharmaceuticals, Inc. (\u201cOlema\u201d, \u201cOlema Oncology\u201d, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women\u2019s cancers, today announced that Sean Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a panel on \u201cER+\/HER2- Breast Cancer\u201d at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference on Thursday, April 20, 2023, at 2:00 p.m. ET. About Olema Oncology Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women\u2019s cancers. Olema\u2019s lead product candidate, OP-1250, is a proprietary, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and &hellip; Continue reading &quot;Olema Oncology to Participate in Canaccord Genuity 2023 Horizons in Oncology Virtual Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-canaccord-genuity-2023-horizons-in-oncology-virtual-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-13T21:45:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNzczMSM1NTI1OTUzIzIyMDM1MTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-canaccord-genuity-2023-horizons-in-oncology-virtual-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-canaccord-genuity-2023-horizons-in-oncology-virtual-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Olema Oncology to Participate in Canaccord Genuity 2023 Horizons in Oncology Virtual Conference\",\"datePublished\":\"2023-04-13T21:45:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-canaccord-genuity-2023-horizons-in-oncology-virtual-conference\\\/\"},\"wordCount\":269,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-canaccord-genuity-2023-horizons-in-oncology-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNzczMSM1NTI1OTUzIzIyMDM1MTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-canaccord-genuity-2023-horizons-in-oncology-virtual-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-canaccord-genuity-2023-horizons-in-oncology-virtual-conference\\\/\",\"name\":\"Olema Oncology to Participate in Canaccord Genuity 2023 Horizons in Oncology Virtual Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-canaccord-genuity-2023-horizons-in-oncology-virtual-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-canaccord-genuity-2023-horizons-in-oncology-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNzczMSM1NTI1OTUzIzIyMDM1MTU=\",\"datePublished\":\"2023-04-13T21:45:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-canaccord-genuity-2023-horizons-in-oncology-virtual-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-canaccord-genuity-2023-horizons-in-oncology-virtual-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-canaccord-genuity-2023-horizons-in-oncology-virtual-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNzczMSM1NTI1OTUzIzIyMDM1MTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNzczMSM1NTI1OTUzIzIyMDM1MTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-to-participate-in-canaccord-genuity-2023-horizons-in-oncology-virtual-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Olema Oncology to Participate in Canaccord Genuity 2023 Horizons in Oncology Virtual Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Olema Oncology to Participate in Canaccord Genuity 2023 Horizons in Oncology Virtual Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-canaccord-genuity-2023-horizons-in-oncology-virtual-conference\/","og_locale":"en_US","og_type":"article","og_title":"Olema Oncology to Participate in Canaccord Genuity 2023 Horizons in Oncology Virtual Conference - Market Newsdesk","og_description":"SAN FRANCISCO, April 13, 2023 (GLOBE NEWSWIRE) &#8212; Olema Pharmaceuticals, Inc. (\u201cOlema\u201d, \u201cOlema Oncology\u201d, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women\u2019s cancers, today announced that Sean Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a panel on \u201cER+\/HER2- Breast Cancer\u201d at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference on Thursday, April 20, 2023, at 2:00 p.m. ET. About Olema Oncology Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women\u2019s cancers. Olema\u2019s lead product candidate, OP-1250, is a proprietary, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and &hellip; Continue reading \"Olema Oncology to Participate in Canaccord Genuity 2023 Horizons in Oncology Virtual Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-canaccord-genuity-2023-horizons-in-oncology-virtual-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-13T21:45:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNzczMSM1NTI1OTUzIzIyMDM1MTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-canaccord-genuity-2023-horizons-in-oncology-virtual-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-canaccord-genuity-2023-horizons-in-oncology-virtual-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Olema Oncology to Participate in Canaccord Genuity 2023 Horizons in Oncology Virtual Conference","datePublished":"2023-04-13T21:45:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-canaccord-genuity-2023-horizons-in-oncology-virtual-conference\/"},"wordCount":269,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-canaccord-genuity-2023-horizons-in-oncology-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNzczMSM1NTI1OTUzIzIyMDM1MTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-canaccord-genuity-2023-horizons-in-oncology-virtual-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-canaccord-genuity-2023-horizons-in-oncology-virtual-conference\/","name":"Olema Oncology to Participate in Canaccord Genuity 2023 Horizons in Oncology Virtual Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-canaccord-genuity-2023-horizons-in-oncology-virtual-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-canaccord-genuity-2023-horizons-in-oncology-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNzczMSM1NTI1OTUzIzIyMDM1MTU=","datePublished":"2023-04-13T21:45:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-canaccord-genuity-2023-horizons-in-oncology-virtual-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-canaccord-genuity-2023-horizons-in-oncology-virtual-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-canaccord-genuity-2023-horizons-in-oncology-virtual-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNzczMSM1NTI1OTUzIzIyMDM1MTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNzczMSM1NTI1OTUzIzIyMDM1MTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-to-participate-in-canaccord-genuity-2023-horizons-in-oncology-virtual-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Olema Oncology to Participate in Canaccord Genuity 2023 Horizons in Oncology Virtual Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/747644","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=747644"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/747644\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=747644"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=747644"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=747644"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}